Latterell Venture Partners
55
25M
27
2.39
7
0.51
19
- Stages of investment
- Areas of investment
Summary
In 2001 was created Latterell Venture Partners, which is appeared as VC. The company was established in North America in United States. The main department of described VC is located in the San Francisco.
The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Latterell Venture Partners, startups are often financed by DeNovo Ventures, Morgenthaler Ventures, Adams Street Partners. The meaningful sponsors for the fund in investment in the same round are The Vertical Group, Morgenthaler Ventures, Adams Street Partners. In the next rounds fund is usually obtained by DeNovo Ventures, Adams Street Partners, Morgenthaler Ventures.
Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. The fund has exact preference in some founders of portfolio startups. If startup sums 3 or 5+ of the founder, the chance for it to be financed is low. Among the most popular portfolio startups of the fund, we may highlight Pulmonx, TetraLogic Pharmaceuticals, Neuraltus Pharmaceuticals. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. We can highlight the next thriving fund investment areas, such as Analytics, Pharmaceutical.
This organization was formed by Larry Lasky, Pat Latterell. Besides them, we counted 2 critical employees of this fund in our database.
The high activity for fund was in 2012. The top amount of exits for fund were in 2016. The usual things for fund are deals in the range of 10 - 50 millions dollars. The real fund results show that this VC is 1 percentage points more often commits exit comparing to other companies. Comparing to the other companies, this Latterell Venture Partners performs on 1 percentage points more the average number of lead investments. The fund is constantly included in 2-6 investment rounds annually.
Investments analytics
Analytics
- Total investments
- 55
- Lead investments
- 7
- Exits
- 19
- Rounds per year
- 2.39
- Follow on index
- 0.51
- Investments by industry
- Health Care (37)
- Biotechnology (34)
- Medical Device (24)
- Medical (22)
- Pharmaceutical (18) Show 15 more
- Investments by region
-
- United States (54)
- South Korea (1)
- Peak activity year
- 2012
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 18
- Avg. valuation at time of investment
- 66M
- Group Appearance index
- 0.96
- Avg. company exit year
- 9
- Avg. multiplicator
- 1.68
- Strategy success index
- 0.30
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
Company name | Deal date | Industry | Deal stage | Deal size | Location |
---|---|---|---|---|---|
MIT Technology Review | 01 Sep 2016 | Internet, News, Digital Media | Seed | 463K | China, Beijing, Haidian District |
PerceptiMed | 27 Mar 2015 | Health Care, Medical Device, Medical | Early Stage Venture | 5M | United States, California, Mountain View |
Talima Therapeutics | 29 May 2007 | Biotechnology, Pharmaceutical, Therapeutics | Early Stage Venture | 19M | United States, California |
Urban SDK | 25 Nov 2020 | Government, Transportation, Software, Analytics, Public Transportation, Smart Cities, Law Enforcement, Civil Engineering | Early Stage Venture | United States, Florida, Jacksonville |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.